Opioid Addiction: Does Starting Buprenorphine Early Help?
7 Oct 2026
A meta-analysis of nine trials with 1,172 people found that starting buprenorphine in the emergency department kept more people in treatment (61% versus 52%) and cut ongoing opioid use (17% versus 28%) compared with brief advice and referral [1]. Most of the trials were from North America and the results varied a lot, so the findings point to the value of starting medicine early rather than proving a fixed benefit [1].
Opioid Addiction at a glance
- What was compared: buprenorphine started in an emergency department versus brief intervention, referral or usual care [1].
- Engagement: 61% with buprenorphine against 52% with brief intervention [1].
- Opioid use: 17% against 28% [1].
- Caution: results varied widely between trials, follow-up was short, and the trials were mainly from North America [1].
What is the evidence on starting buprenorphine early?
Buprenorphine is a medicine that eases opioid withdrawal and craving. It is used as a long-term treatment for opioid use disorder, which is the medical term for addiction to opioids such as heroin or prescription painkillers. The usual question is when to begin. Many people reach a doctor only in a crisis, such as an overdose or withdrawal, and are given advice and a referral instead of a prescription.
The meta-analysis in the Journal of Addictive Diseases pooled nine trials from emergency departments, mostly in North America. It compared starting buprenorphine on the spot with brief intervention (a short counselling conversation), referral, or usual care. Treatment engagement and retention were the main outcomes [1].
How much did early buprenorphine help?
People started on buprenorphine were more likely to stay in treatment, at 61% compared with 52% after brief intervention. Opioid use was also lower, at 17% against 28%. Brief intervention alone showed minimal effects on treatment use, overdose risk or drug use [1].
An earlier randomised trial in 329 opioid-dependent patients showed the same pattern. At 30 days, 78% of the buprenorphine group were in treatment, against 37% of the referral group and 45% of the brief-intervention group. Illicit opioid days per week fell from 5.4 to 0.9 in the buprenorphine group [3]. That trial did not find a difference in urine tests for opioids, and the authors said the findings needed to be replicated elsewhere [3].
Does the form of buprenorphine matter?
A large 2026 trial across 29 US emergency departments compared a 7-day extended-release injection with the usual tablets placed under the tongue. Among 1,994 patients, treatment engagement at day 7 was similar, 40.5% with the injection and 38.5% with the tablets. People on the injection reported lower craving, fewer days of illicit opioid use and a little more satisfaction. Precipitated withdrawal was rare in both groups [2].
| Study | Comparison | Main finding |
|---|---|---|
| Meta-analysis, 9 trials | Buprenorphine versus brief intervention or usual care | 61% versus 52% engaged; opioid use 17% versus 28% |
| Randomised trial, 329 patients | Buprenorphine versus referral or brief intervention | 78% versus 37% and 45% in treatment at 30 days |
| Randomised trial, 1,994 patients | Injection versus tablets | Similar engagement at 7 days; lower craving with injection |
Key results on starting buprenorphine early [1,2,3].
What are the limits of this evidence?
The meta-analysis found extreme heterogeneity (I² about 99%), possible publication bias, short follow-up and little data outside North America [1]. In plain terms, trials disagreed with each other, so any single percentage should be read loosely. These studies also took place in emergency departments, in a different health system from most Indian care pathways. They show that starting medicine early works better than advice alone. They don't tell you how a treatment programme in India should be organised.
What does this mean for a family in crisis?
Medicine is one part of treatment. Counselling, relapse-prevention planning, treatment of depression or anxiety, and family involvement all shape how long recovery lasts. Opioid withdrawal and any suspected overdose need urgent medical care. Do not try to manage them alone at home.
If someone is unconscious, breathing slowly or cannot be woken, call 112 immediately. For emotional distress or thoughts of self-harm, Tele-MANAS (14416) offers free support round the clock.
Getting help in Delhi
Brain Bridge Clinic in Safdarjung Enclave, New Delhi, has a de-addiction clinic and rehab programmes that combine assessment, supervised withdrawal management where needed, counselling and relapse-prevention support. A first assessment covers substance use history, physical health, mood and family situation, so a plan can be built around the person. Families are welcome to ask for an appointment to talk through options.
Related pages: De Addiction, De Addiction Rehab Programs, Relapse Prevention Programs.
Frequently asked questions
What is buprenorphine used for?
It is a medicine used in the treatment of opioid use disorder. It eases withdrawal and craving, which can help people stay in treatment [1].
Is medicine better than counselling alone for opioid addiction?
In emergency-department trials, starting buprenorphine kept more people in treatment than brief intervention and referral did [1,3]. Counselling still has an important place alongside medicine.
Is an injection better than tablets?
A 2026 trial found similar treatment engagement at 7 days, with lower craving and fewer days of illicit opioid use for those on the injection [2]. Which suits you is a decision with your doctor.
Do these results apply in India?
The trials were mainly from North America. They show that starting medicine early helps, but they weren't designed around Indian patients or services [1].
What should I do if someone has overdosed?
Call 112 straight away. Do not wait for symptoms to settle at home.
References
- Bavali-Gazik A, Hosseini SN, Salehian S, et al. Emergency department-initiated buprenorphine vs brief intervention for opioid use disorder: a systematic review and meta-analysis of clinical trials. Journal of addictive diseases. 2026;44(4):487-500. doi:10.1080/10550887.2025.2605451. PMID 41477698.
- D'Onofrio G, Herring AA, Hawk KF, et al. Emergency Department-Initiated Buprenorphine for Opioid Use Disorder: A Randomized Clinical Trial. JAMA. 2026;335(11):948-960. doi:10.1001/jama.2025.27019. PMID 41670966.
- D'Onofrio G, O'Connor PG, Pantalon MV, et al. Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial. JAMA. 2015;313(16):1636-44. doi:10.1001/jama.2015.3474. PMID 25919527.